Anti-Infective Drugs Advisory Committee

January 30, 2001

NDA 50-755 Augmentin (amoxicillin/clavulantate potassium)

Briefing Information

Food and Drug Administration

Briefing Information   doc   pdf

SmithKline Beecham

Disclaimer

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Briefing Information